Marco Garbayo José Luis, Koninckx Cañada Manuel, Pérez Castelló Isabel, Faus Soler María Teresa, Fuster Torres Rosa, Moncho Escrivà Mar
Department of Hospital Pharmacy, Francesc de Borja Hospital of Gandia, Valencia, Spain.
Department of Clinical Documentation and Admission, Francesc de Borja Hospital of Gandia, Valencia, Spain.
Eur J Hosp Pharm. 2017 Nov;24(6):355-360. doi: 10.1136/ejhpharm-2016-001087. Epub 2016 Nov 7.
To analyse the risk factors of gastropathy caused by using non-steroidal anti-inflammatory drugs (NSAIDs) in detected hospital admissions and to analyse the use of gastroprotective treatment concerning these risk factors.
A retrospective observational study was carried out in the framework of an integral risk management plan of drugs and proactive pharmacovigilance of hospital admissions for NSAID-induced gastropathy occurring between 2011 and 2015. Cases were identified after reviewing the ICD-9 codes related to NSAID-induced gastropathy in hospital discharge reports. Various biometric, clinical and pharmacotherapeutic variables of each patient were registered. The gastroprotective criteria set out in the therapeutic decision algorithm of the Valencian Health System were followed.
62 hospital admissions for NSAID-induced gastropathy were detected. The mean length of stay was 5.3±3.8 days. Ibuprofen was the most prevalent NSAID (28 cases, 45.2%). 24 cases (38.7%) took NSAIDs in the week before hospitalisation. The prevalence of relevant risk factors for gastropathy were age >60 years (37 cases, 59.7%), concomitant medication (24 cases, 38.7%) and a history of peptic ulcer (9 cases, 14.5%). 41 patients (66.1%) met gastroprotective major criteria, 18 of whom (43.9%) were using a proton pump inhibitor following a prevention plan.
In this study all relevant gastroprotective criteria were associated with the use of gastroprotection in detected hospital admissions for NSAID-induced gastropathy. However, a lack of gastroprotection was observed in a large number of detected cases with the criteria to use it. The feedback of our results to health area agents can serve to reinforce the safe use of NSAIDs.
分析在已确诊的住院病例中使用非甾体抗炎药(NSAIDs)导致胃病的危险因素,并分析针对这些危险因素的胃保护治疗的使用情况。
在2011年至2015年期间发生的NSAID引起的胃病住院患者的药物综合风险管理计划和主动药物警戒框架内进行了一项回顾性观察研究。通过审查医院出院报告中与NSAID引起的胃病相关的ICD-9编码来确定病例。记录了每位患者的各种生物统计学、临床和药物治疗变量。遵循瓦伦西亚卫生系统治疗决策算法中规定的胃保护标准。
检测到62例因NSAID引起的胃病住院病例。平均住院时间为5.3±3.8天。布洛芬是最常见的NSAID(28例,45.2%)。24例(38.7%)在住院前一周服用了NSAIDs。胃病相关危险因素的患病率为年龄>60岁(37例,59.7%)、合并用药(24例,38.7%)和消化性溃疡病史(9例,14.5%)。41例患者(66.1%)符合胃保护主要标准,其中18例(43.9%)按照预防计划使用质子泵抑制剂。
在本研究中,所有相关的胃保护标准都与在已确诊的NSAID引起的胃病住院病例中使用胃保护措施相关。然而,在大量符合使用标准的已确诊病例中观察到缺乏胃保护措施的情况。将我们的结果反馈给卫生领域的相关人员有助于加强NSAIDs的安全使用。